Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A study published in the Journal of Leukocyte Biology found that histamine plays a role in protecting tumors from the immune system. By blocking histamine production, researchers were able to interrupt a process promoting melanoma growth.
Researchers have identified a key pathway that helps cancer cells survive in low-glucose environments, and found that certain diabetes drugs can inhibit this pathway to kill cancer cells. The study provides new insights into how anti-cancer properties of diabetes drugs like metformin may work.
Scientists have discovered two novel genes linked to angiosarcoma, a rare and aggressive cancer of blood vessels. The study found that these genes are mutated in nearly 40% of cases, suggesting potential new targets for treatment.
Researchers have developed a novel approach to treating CLL by disrupting the activity of the NF-kappaB pathway, which ensures survival and resistance of CLL cells. This approach may lead to re-sensitization of CLL cells to conventional chemotherapy and novel agents.
A phase I trial found a complete response for 14 months to everolimus and pazopanib in a patient with advanced bladder cancer and rare mTOR genetic mutations. Genomic profiling revealed two alterations that activated the mTOR-mediated cell signaling pathway, rendering the cancer sensitive to the mTOR inhibitor.
Researchers identify two rare mutations in the mTOR gene associated with a complete response to everolimus and pazopanib, leading to improved treatment options for patients. The study provides new insights into personalized medicine and targeted therapies for bladder cancer.
Researchers developed a novel therapy combining cryoablation with nanodrug chemotherapy to eliminate cancer stem-like cells. The treatment showed significant promise in eradicating CSCs, reducing the risk of cancer recurrence and metastasis. This innovative approach has great potential for improving cancer treatment outcomes.
A new clinical study found that erlotinib significantly improved treatment outcomes for women with locally advanced cervical cancer. After two years, 91.7% of patients were alive and experienced no disease progression.
Researchers found that several chemotherapy drugs cause hyper proliferation in stem cells, leading to tumor recurrence. The study used fruit flies as a model, discovering compounds that inhibit tumors without causing this side effect.
A study by The Institute of Cancer Research identified mutations in the DNA methyltransferase gene, DNMT3A, in 13 children with a newly described condition called 'DNMT3A overgrowth syndrome'. The condition causes intellectual disability and unusual growth in children, but has no link to cancer risk.
Researchers have discovered that FDA-approved anti-psychotic drugs possess tumor-killing activity against glioblastoma. The finding is based on shRNA technology that identifies genes required for glioblastoma growth and reveals surprising links to dopamine regulation, a crucial component in treating Parkinson's disease and schizophrenia.
A new study published in Circulation reveals how changes in the organized cell membrane network of heart muscle leads to heart failure. Colchicine, a drug used for gout treatment, protects normal heart function by reducing microtubule density, while taxol accelerates damage during heart failure.
Researchers at UT Southwestern Medical Center have identified a key protein target for shutting down the growth of prostate cancer cells. ERG protein is transformed into cancer cells by an enzyme called USP9X, but a molecule called WP1130 can block this process.
Patients receiving nivolumab survived for an average of 16.8 months, with 62% alive one year after treatment initiation and 43% alive two years later. The drug also shrank tumors in 31% of patients, with some able to remain on the treatment for up to two years.
A new study by Dana-Farber Cancer Institute and Johns Hopkins University found that an immune system-based therapy called nivolumab can produce lasting remissions in melanoma patients, with some patients remaining alive after two years without treatment. The therapy has been shown to block PD-1, a protein that restrains the immune syst...
Researchers at Norris Cotton Cancer Center have developed an antibody that targets the ProAVP surface marker in small-cell lung cancer. The antibody, MAG-1, significantly slows tumor growth in mice and has shown promise as a potential treatment for recurrent small-cell lung cancer.
Researchers have found that an ancient Chinese medicine extract blocks pathways to treat pancreatic cancer by inhibiting scarring and inflammation. The compound also appears to suppress Cox-2, an enzyme that causes inflammation, and has been shown to be safe for use in patients.
A new study comparing prescription data from England and Wales has found that patients in England are up to seven times more likely to be prescribed expensive cancer drugs than their counterparts in Wales. The Cancer Drugs Fund has created an inequality in access to these treatments, raising ethical, moral, financial, and policy concerns.
Researchers have developed a new laboratory screening technique to find novel treatments for pediatric neuroblastoma. MicroRNAs play an important role in regulating cell development and differentiation, revealing promising targets for new therapies.
Researchers developed nanoparticles that absorb energy from infrared red wavelength and release chemotherapy drugs when triggered by two-photon laser. The delivery system shows promise for treating cancer with reduced treatment side effects and increased cancer-killing effect.
A randomized, double-blind trial of 621 adults found that Bevacizuman did not prolong survival for newly diagnosed glioblastoma patients. The results contradict earlier studies showing the drug's effectiveness in other diseases.
A new protein called Merm1 has been discovered to play a role in controlling cell growth and division in lung tissue. This finding could lead to the development of new drugs targeting lung cancer.
A UCLA research team has developed a treatment that blocks two metabolic pathways needed by leukemia cells, halting their growth and leading to cell death. The experimental treatment showed promising results in mice with acute lymphoblastic leukemia.
The American Academy of Pediatrics (AAP) has updated its policy on the off-label use of drugs in children, offering guidance for physicians to ensure safe and effective treatment. The new recommendations aim to improve drug safety and efficacy in pediatric patients, particularly those with special needs or rare diseases.
Researchers at Tel Aviv University propose a new nanoscale drug-delivery system to tackle aggressive ovarian cancer using a cluster of nanoparticles called gagomers. The system accumulates in tumors, producing dramatic therapeutic benefits and reducing toxic accumulation in healthy organs.
Researchers found that a cancer medication reduces sudden cardiac death risk in mice with abnormal heartbeats and heart failure. This promising treatment option could provide patients and clinicians with a new paradigm for treating life-threatening illness.
A Phase III clinical trial found no significant improvement in overall survival or progression-free survival with bevacizumab treatment for new glioblastoma patients. Researchers also observed increased symptoms and neurocognitive decline among non-progressing patients treated with bevacizumab.
A University of Colorado study used a COXEN model to match tumors with optimal drugs, significantly extending patient survival. The model analyzed genetic data from thousands of tumor samples to identify response patterns.
A four-year clinical study involving 461 patients with advanced cancers showed that earlier palliative care significantly improved quality of life and patient satisfaction. The study demonstrated the benefits of cancer centers providing early specialized palliative care in outpatient clinics.
Researchers aim to develop nanoparticles that target prostate cancer cells with a genotoxin drug. The nanoparticles will also promote healing in damaged blood vessels by mimicking platelets and catching circulating endothelial progenitor cells.
A pre-clinical study suggests that dinaciclib, a CDK inhibitor, can improve the effectiveness of certain therapies for multiple myeloma and myeloid leukemia by disrupting the unfolded protein response (UPR) in cancer cells. The UPR is a cell survival mechanism that allows cancer cells to combat damage caused by anti-cancer agents.
A new method for purifying peptide-based drugs has been developed by a chemist at Michigan Technological University, separating perfect peptides from those that don't make the grade in just two hours. The process reduces waste and is cheaper than existing methods, offering a promising alternative for treating diseases like cancer and HIV.
Cancer doctors can cut costs without risk to patients by improving end-of-life care, reducing unnecessary medical imaging, and negotiating lower prices for new cancer drugs. These changes can save billions of dollars in healthcare spending while maintaining quality of life.
A study found tamoxifen, a breast cancer treatment, in three out of four samples of the bodybuilding supplement Esto Suppress. The product label suggested a dosage that may provide enough to treat gynaecomastia. Off-the-shelf supplements have been known to contain pharmacologically active substances, posing risks to users.
Researchers have discovered how the protein Bcl-2 signals cancer cells to live longer by altering calcium ion levels. This breakthrough could lead to new drugs targeting Bcl-2 and improve cancer treatment outcomes.
University of Pittsburgh Cancer Institute scientists have found several potential possibilities to try if the cancer becomes resistant to standard drug treatment. They discovered that high-throughput screening of already FDA-approved drugs can identify new therapies that could be rapidly moved to the clinic.
The 'Viewpoint' article highlights the complexity of developing genome-based therapeutics and companion diagnostics, which depend on multiple genetic tests. The authors argue for a unified plan to co-develop and co-submit diagnostic tests that predict drug benefit, addressing regulatory, business, and economic challenges.
Researchers discovered tamoxifen can kill Cryptococcus germ by interfering with a protein, offering potential new treatment for deadly brain infection. Additional animal experiments are needed to develop new anti-cryptococcal drugs based on the findings.
Researchers at UT Health Science Center identified a key role of the WTAP protein in AML development and found that suppressing it with Hsp90 inhibition greatly suppressed proliferation and induced differentiation. This discovery opens up new avenues for effective therapies for children and adults with newly diagnosed AML.
Researchers discovered tamoxifen, a breast cancer treatment, also kills Cryptococcus, a fungus causing deadly brain infections. The combination of tamoxifen and fluconazole was synergistic, showing improved activity against the fungus. This finding offers a new approach to treating cryptococcal meningitis.
A panel of 55 genes impacted by loss of protein SYK predicts invasive breast cancer, with better survival rates for patients without gene changes. Researchers found that 80% of patients without genetic alterations were still alive after 18 years, compared to 20% with gene changes.
Researchers at NYU Langone Health have found a biological weakness in mutant K-Ras, the most commonly mutated gene involved in human cancers. By blocking the activity of related genes H-Ras and N-Ras, chemotherapy drug irinotecan can stall tumor growth.
Researchers at Scripps Research Institute create Inforna, a technique to identify potent compounds targeting cancer-causing microRNAs. The method enables unprecedented targeting of disease-associated RNAs, offering a promising approach to designing novel anti-cancer drugs.
Researchers at CNIO propose a new combined therapy to treat cancer by combining etoposide with compounds that interfere with the cell cycle, increasing specificity and improving the therapeutic window. This approach aims to reduce toxicity and increase effectiveness in treating tumour cells.
Researchers have discovered that JAK inhibitors, currently used to treat blood disorders, can reduce the growth of inflammation-associated stomach and bowel cancer. The study provides evidence supporting their use in treating these cancers.
A group of experts has proposed concrete steps to prevent and manage drug shortages, including sharing scarce drugs and giving equal priority to patients. The 'blueprint for action' aims to move away from reactive strategies and focus on prevention, ensuring life-saving medications are accessible to children with cancer and beyond.
A single dose of rituximab significantly reduces kidney relapses in children and young adults with frequently-replapsing idiopathic nephrotic syndrome, allowing for discontinuation of standard immunosuppressive medications. The treatment is also well-tolerated and improves kidney function.
Researchers identified UHRF1 as a key driver of liver cancer in zebrafish models and human tumors, showing that high levels of UHRF1 can cause tumors to form rapidly. The study suggests that targeting UHRF1 could be an effective approach to halting cancer formation and offers new hope for treatments for hepatocellular carcinoma.
A new biological pathway-based computational model, called PHPN, mines large publicly available disease datasets to find shared genetic connections between diseases. The model offers a visual representation of the relationships between diseases and phenotype's at the systems level.
Researchers have identified potential therapeutic targets for muscle-invasive bladder cancer, including genes and pathways disrupted in the disease. The study also found similarities between subtypes of bladder cancer and those of other cancers, such as breast, head and neck, and lung cancers.
Researchers have identified 32 genes with recurring defects in muscle-invasive bladder cancer, offering a roadmap for targeted treatments. The study also found frequent alterations in chromatin regulation and viral DNA involvement in bladder cancer development.
A study found that patients with ALK+ non-small cell lung cancer can continue treating with crizotinib after receiving targeted radiation therapy to eliminate resistant disease pockets. This approach improves 2-year survival rates compared to those who discontinued the drug earlier.
Researchers have discovered a new combination therapy that leverages existing experimental therapies to speed the fight against cancer. The approach, which combines SMAC Mimetics with live virus therapies, shows a synergistic tumour-killing effect, overcoming limitations of individual agents.
Researchers at the University of Toronto have developed a method to assemble gold nanoparticles using DNA as a vehicle to deliver cancer medications or markers directly into cancerous tumors. The particles can be precisely engineered to target specific tumor types and stages.
Scientists have discovered a critical weakness in the microscopic transport system within cells, which could be targeted for cancer treatment. The study reveals that a narrow seam along microtubules is the weakest point, leading to its dissolution when cracked or split.
A recent study by Loyola Medicine finds that many internists feel ill-equipped to care for adult childhood cancer survivors due to inadequate education and training. The study highlights the need for primary care physicians to have access to survivorship care plans and guidelines.
A landmark study across many cancer types reveals that the universe of cancer mutations is much bigger than previously thought. The team's work expands the list of known genes tied to these cancers by 25 percent.
A new study published in the New England Journal of Medicine finds that idelalisib reduces tumor size by at least half in 57% of patients with indolent non-Hodgkin lymphoma. The drug's side effects are manageable, offering a targeted and less harmful approach to treating cancer.
Scientists at Weill Cornell Medical College have found that a twice-daily pill, idelalisib, can turn deadly blood cancer into a highly treatable disease. The study suggests that patients with CLL may avoid debilitating chemotherapy, leading to significant side effects and death.
The Jackson Laboratory will receive a five-year, $7.5 million grant to develop new mouse models and tumor repository for cancer genomics research. The collaboration with Seoul National University aims to advance individualized cancer diagnosis and treatment.